References

  1. Choi HD, Kim KK, Koo BH. A case of catatonia and neuroleptic malignant syndrome probably associated with antipsychotic in Korea. Psychiatry Investig. 2011 Jun;8(2):174-7. PubMed | Google Scholar

  2. Gallelli L, Spagnuolo V, Palleria C et al. A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman. Curr Drug Saf. 2009 May;4(2):119-20. PubMed | Google Scholar

  3. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010 Sep 15;25(12):1780-90. PubMed | Google Scholar

  4. Musselman ME, Browning LA, Parker D et al. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome. Ann Pharmacother. 2011 Nov;45(11):e61. PubMed | Google Scholar

  5. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870-6. PubMed | Google Scholar

  6. Wysokinski A. Intensive electroconvulsive therapy in drug resistant neuroleptic malignant syndrome - case report. Psychiatr Danub. 2012 Jun;24(2):219-22. PubMed | Google Scholar

  7. Janati AB, Alghasab N, Osman A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. Case Rep Neurol Med. 2012;2012:183252. PubMed | Google Scholar

  8. Themistocleous MS, Boviatsis EJ, Stavrinou LC et al. Malignant neuroleptic syndrome following deep brain stimulation surgery: a case report. J Med Case Rep. 2011 Jun 29;5:255. PubMed | Google Scholar

  9. Rais AR, Kimmel S, Shrestha N et al. Atypical neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol. 2008 Apr;18(2):215-20. PubMed | Google Scholar

  10. Stubner S, Rustenbeck E, Grohmann R et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S54-64. PubMed | Google Scholar

  11. Yanagawa Y, Miyazaki M. Case with difficulty in differentiating between transient neuroleptic malignant syndrome and catatonia after neuroleptic analgesia. Masui. 2010 Feb;59(2):235-7. PubMed | Google Scholar

  12. Chen Y, Guo JJ, Steinbuch M et al. Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based case-control study. Int J Psychiatry Med. 2009;39(4):439-50. PubMed | Google Scholar

  13. Keck PE Jr, Pope HG Jr, Cohen BM et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989 Oct;46(10):914-8. PubMed | Google Scholar

  14. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000 Jul;85(1):129-35. PubMed | Google Scholar

  15. Tsai MC, Huang TL. Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report. Chang Gung Med J. 2010 Sep-Oct;33(5):576-80. PubMed | Google Scholar